President Donald Trump appointed journalist Sara Carter as the subsequent director of the Workplace of Nationwide Drug Management Coverage (ONDCP), or the “drug czar,” reported Fox Information, quoting the president’s feedback on social media.
“It’s my nice honor to announce Sara Carter as our subsequent Director of the Workplace of Nationwide Drug Management Coverage (ONDCP). Sara is an Award Successful Journalist, who has been on the entrance traces of this Worldwide Battle for many years,” Trump wrote on Fact Social. “From Afghanistan to our Border, Sarah’s relentless pursuit of Justice, particularly in tackling the Fentanyl and Opioid Disaster, has uncovered terrorists, drug lords, and intercourse traffickers. As our subsequent Drug Czar, Sara will lead the cost to guard our Nation, and save our kids from the scourge of medicine.
Like most of Trump’s appointees and cupboard members, Carter is a former Fox Information contributor who has referred to as for stronger border insurance policies.
What units her aside is that Carter has referred to as medical marijuana a “implausible” therapy for severely unwell folks and apparently, she has no drawback with legalizing hashish. However, it isn’t her cup of tea.
“I haven’t got any drawback if it is legalized and it is monitored,” she mentioned in her podcast The Sara Carter Present, reported Marijuana Second. “I imply, I could have my very own problems with how I really feel about that, however I do imagine that hashish for medicinal functions and medical causes is a implausible approach of dealing with — particularly for folks with most cancers and different sicknesses, you recognize — of dealing with the sickness and the uncomfortable side effects of the treatment and people sicknesses. So I am not saying we have gotta make it unlawful.”
Throughout his presidential marketing campaign, Trump himself made overtures to that very same concept. Nevertheless, he has since barely talked about the thought of federally legalizing hashish and welcoming the $30 billion trade into the fold.
Now Learn:
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
